Fluvastatin

REFERENCES

• STAMLER J, WENTWORTH D, NEATON JD: Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA (1986) 256:2823–2828.
   PubMed Web of Science ®Google Scholar
• KANNEL WB, CASTELLI WP, GORDON T, McNAMARA PM: Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study. Ann. Intern. Med. (1971) 74(1):1–12.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1388.
   PubMed Web of Science ®Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl. Med. (1996) 335: 1001–1009.
   PubMed Web of Science ®Google Scholar
• THE LONG TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl. Med. (1998) 339(19):1349–1357.
   PubMedGoogle Scholar
• SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl. Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA (1998) 279(20):1615–1622.
   PubMed Web of Science ®Google Scholar
• COLLINS R, PETO R, ARMITAGE J: The MRC/BHF Heart Protection Study: preliminary results. Lit. I Clin. Pract. (2002) 56(1):53–56.
   PubMedGoogle Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360:7–22.
   PubMed Web of Science ®Google Scholar
• SCRIPTURE CD, PIEPER JA.: Clinicalpharmacokinetics of fluvastatin. Clin. Pharmacokinet. (2001) 40(4):263–281. Extensive review of pharmacokinetics of fluvastatin.
   Google Scholar
• LYE M, VALACIO R, RECKLESS JP et al.: Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin. Coron. Artery Dis. (1998) 9(9):583–590.
   PubMedGoogle Scholar
• APPEL-DINGEMANSE S, SMITH T, MERZ M: Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome. J. Clin. Pharmacol (2002) 42(3):312–318.
   PubMedGoogle Scholar
• LINTOTT CJ, SCOTT RS, BREMER JM: Fluvastatin for dyslipidaemia with or without concomitant chronic renal insufficiency. Am. J. Cardin]. (1995) 76(2):97A-101A.
   Google Scholar
• SAMUELSSON 0, ATTMANN PO, KNIGHT-GIBSON C, MULEC H, WEISS L, ALAUPOVIC P: Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. Am. j Kidney Dis. (2002) 39(1):67–75.
   PubMed Web of Science ®Google Scholar
• BALLANTYNE CM, MCKENNY J, TRIPPE BS: Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolaemia. Am. Cardiol. (2000) 86:759–763.
   PubMedGoogle Scholar
• SABIA H, PRASAD P, SMITH HF, STOLTZ RR, ROTHENBERG P: Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolaemia. Cardiovasc. Pharmacol. (2001) 37(5):502–511.
   PubMedGoogle Scholar
• IGEL M, SUDHOP T, VON BERGMANN K: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur. Clin. Pharmacol. (2001) 57:357-364. ••Extensive review comparing potential druginteractions of all statin drugs currently on the market.
   Google Scholar
• CHONG PH, SEEGER JD, FRANKLIN C: Clinically relevant differences between the statins: Implications for therapeutic selection. Am.! Med. (2001) 111:390-400. •Helpful review highlighting important differences between statins especially with regard to potential drug interactions.
   Google Scholar
• WEISE WJ, POSSIDENTE CJ: Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient. Am. j Med. (2000) 108(4):351–352.
   PubMedGoogle Scholar
• MALTZ HC, BALOG DL, CHEIGH JS: Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann. Pharmacother. (1999) 33(11):1176–1179.
   PubMedGoogle Scholar
• HERMIDA LAZCANO I, REVILLO PINILLA P, NERIN SANCHEZ C, LECHUGA DURAN I, FERNANDEZ LOPEZ J: Rhabdomyolysis in a patient treated with lovastatin and cyclosporine. An. Med. Interne (1997) 14(9):488.
   PubMedGoogle Scholar
• PARK JW, SIEKMEIER R, LATTKE P et al.: Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine a. Cardiovasc. Pharmacol. Then (2001) 6(4):351–361.
   PubMedGoogle Scholar
• JARDINE A, HOLDAAS H: Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience. J. Clin. Pharm. Ther. (1999) 24(6):397–408.
   PubMedGoogle Scholar
• HOLDAAS H, FELLSTROM B, HOLME I et al.: Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (assessment of lescol in renal transplantation) study design and baseline data." Cardiovasc. Risk (2001) 8(2):63–71. ••Important study of use of statins in renaltransplant patients.
   Google Scholar
• KLINE SS, HARRELL CC: Potential warfarin-fluvastatin interaction. Ann. Pharmacother. (1997) 31(6):790.
   PubMedGoogle Scholar
• TRILLI LE, KELLEY CL, ASPINALL SL, KRONER BA: Potential interaction between warfarin and fluvastatin. Ann. Pharmacother. (1996) 30(12):1399–1402.
   PubMed Web of Science ®Google Scholar
• LANGTRY HD, MARKHAM A: Fluvastatin: a review of its use in lipid disorders. Drugs (1999) 57(4):583–606. ••Extensive review of trial evidence andclinical use of fluvastatin.
   Google Scholar
• DAVIDSON MH: Fluvastatin Long-Term Extension Trial (FLUENT): Summary of efficacy and safety. Am. J. Med. (1994) 96 (Suppl. 6A):415–445.
   Google Scholar
• BANGA JD, JACOTOT B, PFISTER P, MEHRA M: Long-term treatment of hypercholesterolaemia with fluvastatin: A 52-week multicenter safety and efficacy study. Am. I Med. (1994) 96(Suppl. 6A):875–935.
   Google Scholar
• Prevention of coronary heart disease: scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Num. Metab. Cardiovasc. Dis. (1992) 2:113–156
   Google Scholar
• BALLANTYNE CM, PAZZUCCONI F, PINTO X et al.: Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin. Ther. (2001) 23(2):177–192. •Summary of a number of trials of fluvastatin XL.
   Google Scholar
• HERD JA, BALLANTYNE CM, FARMER JA et al.: Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study [LCAS1). Am. J. Cardiol. (1997) 80:278-286. •First trial results with outcome data for fluvastatin.
   Google Scholar
• BALLANTYNE CM, HERD JA, FERLIC LL et al: Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation (1999) 99:736–743.
   PubMed Web of Science ®Google Scholar
• BLANKENHORN DH, NESSIM SA, JOHNSON RL, SANMARCO ME, AZEN SP, CASHIN-HEMPHILL L: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA (1987) 257:3233–3240.
   PubMed Web of Science ®Google Scholar
• STEWART BE BROWN BG, ZHAO X-Q et al.: Benefits of lipid lowering therapy in men with elevated apolipoprotein B are not confined to those with high low density lipoprotein cholesterol. Am. Coll. Cardiol (1994) 23:899–906.
   Google Scholar
• JUKEMA JW, BRUSCHKE AVG, VAN BOVEN AJ et al.: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Study (REGRESS). Circulation (1995) 91:2528–2540.
   Google Scholar
• RIEGER G, ABLETSHAUSER C, LUDWIG M et al: The effect of fluvastatin on cardiac events in patients with symptomatic coronary heart disease during one year of treatment. Atherosclerosis (1999) 144:263–270.
   PubMedGoogle Scholar
• SERRUYS PW, FOLEY DP, JACKSON G et al.: A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty. Final results of the fluvastatin angiographic restenosis (FLARE) trial. Ear: Heart 1(1999) 20:58–69.
   Google Scholar
• WALTER DH, SCHACHINGER V, ELSNER M, MACH S, AUCH-SCHWELK W, ZEIHER AM: Effect of statin therapy on restenosis after coronary stent implantation. Am. J. Cardiol (2000) 85:962–968.
   PubMed Web of Science ®Google Scholar
• SERRUYS PW, DE FEYTER P, MACAYA C et al: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. "AMA (2002) 287:3215-3222 ••Important study with outcome datashowing benefit in early treatment with fluvastatin after a percutaneous coronary intervention.
   Google Scholar
• ANDREWS TC, BALLANTYNE CM, HSIA JA, KRAMER JH: Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. Am. J. Med. (2001) 111:185-191. •Comparison between the effectiveness of fluvastatin and other statins in lipid lowering.
   Google Scholar
• Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA (2001) 285(19):2486–2497. •• ••Recently released NCEP guidelines for management of hypercholesterolaemia.
   Google Scholar
• JONES PH, KAFONEK S, LAURORA I, HUNNINGHAKE D: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolaemia (The CURVES study). Am. J. Cardiol (1998) 81:582-587. •Comparison between the effectiveness of fluvastatin and other statins in lipid lowering.
   Google Scholar
• MACLAINE GDH, PATEL H: A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels. Int. J. Clin. Pract. (2001) 55 (4) : 243–249. •Comparitive study of cost effectiveness of different statins suggesting fluvastatin may not be most cost effective.
   Google Scholar
• KOREN MJ, SMITH DG, HUNNINGHAKE DB et al: The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics (1998) 14(1):59–70. •Comparitive study of cost effectiveness of different statins suggesting fluvastatin may not be most cost effective.
   Google Scholar
• BALLANTYNE CM, CORSINI A, DAVIDSON MH et al.: Risk for myopathy with statin therapy in high-risk patients. Arch. hat. Med. (In Press).
   Google Scholar
• BENGHOZI R, BORTOLINI M, JIA Y,ISAACSOHN JL, TROENDLE AJ, GONASUN L: Frequency of creatine kinase elevation during treatment with fluvastatin. Am.! Cardiol (2002) 89:231–233.
   PubMed Web of Science ®Google Scholar
• OMAR MA, WILSON JP: FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmacother. (2002) 36(2):288–295. •Data from FDA showing low rate of rhabdomyolysis with fluvastatin but highlighting patients should still be warned of this important side effect of statins.
   Google Scholar
• STAFFA JA, CHANG J, GREEN L: Cerivastatin and reports of fatal rhabdomyolysis. N Eng. J. Med. (2002) 346(7):539–540.
   PubMed Web of Science ®Google Scholar
• UCAR M, MJORNDAL T, DAHLQVIST R: HMG-CoA reductase inhibitors and myotoxicity. Drug Sal (2000) 22(6):441–457.
   PubMed Web of Science ®Google Scholar
• ELIAV 0, SCHURR D, PFISTER P, FRIEDLANDER Y, LEITERSDORF E: High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolaemia. Am. J. Cardiol (1995) 76:76A–79A.
   Google Scholar
• FARNIER M, DEJAGER S: Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolaemia. Am. Cardiol (2000) 85:53–57.
   PubMed Web of Science ®Google Scholar
• PAUCIULLO P, BORGNINO C, PAOLETTI R, MARIANA M, MANCINI M: Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerotic (2000) 150:429–436.
   PubMed Web of Science ®Google Scholar
• BELLOSTA S, FERRI N, BERNINI F, PAOLETTI R, CORSINI A: Non-lipid-related effects of statins. Ann. Med. (2000) 32:164–176
   PubMed Web of Science ®Google Scholar
• ROSS R: Atherosclerosis - an inflammatorydisease. N Eng. J. Med. (1999) 340: 115–126.
   PubMed Web of Science ®Google Scholar
• CORSINI A: Fluvastatin: Effects beyondcholesterol lowering. Cardiovasc. Pharmacy]. Therapeut. (2000) 5:161–175.
   PubMedGoogle Scholar